Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
54.14
-0.57 (-1.04%)
Official Closing Price
Updated: 7:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
September 18, 2024
Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.
Via
Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
September 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
What Analysts Are Saying About Bristol-Myers Squibb Stock
September 16, 2024
Via
Benzinga
Current Report: Bristol-Meyers Squibb (BMY)
September 16, 2024
The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout!
Via
Talk Markets
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
September 16, 2024
Now could be a great time to scoop up three stocks trading way below their previous peaks.
Via
The Motley Fool
Merck Scores Two Key Victories With Keytruda In Women's Cancers
September 15, 2024
The company also unveiled 10-year test results for Keytruda in advanced melanoma patients.
Via
Investor's Business Daily
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
September 15, 2024
From
Bristol Myers Squibb
Via
Business Wire
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
These two stocks have had their issues in recent years, but both look like reliable long-term bets.
Via
The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
September 12, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend
September 10, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?'
September 09, 2024
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...
Via
Benzinga
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
September 09, 2024
From
Bristol Myers Squibb
Via
Business Wire
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
September 08, 2024
These dividend payers could more than double their payouts in the decade ahead.
Via
The Motley Fool
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
September 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
September 02, 2024
Rebounding growth could make shares of this leading drugmaker a big winner.
Via
The Motley Fool
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
September 01, 2024
No stock is perfect, but quality businesses can stand the test of time in your portfolio.
Via
The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
September 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 30, 2024
The Benzinga Stock Whisper Index looks at five stocks seeing above average interest from investors during the week.
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.
Via
Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
August 28, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.
Via
Investor's Business Daily
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
August 28, 2024
Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.
Via
The Motley Fool
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
August 28, 2024
These underappreciated dividend payers offer yields above 4% at recent prices.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.